Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Dirks

Showing results (191-200 of 226) with videos related to

Pageof 23
Sort By:
Cancer Cell|May 16, 2019
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M GliomasBrian Krug, Nicolas De Jay, Ashot S Harutyunyan, et al.
Nucleic Acids Research|April 30, 2025
PRMT5 promotes full-length HTT expression by repressing multiple proximal intronic polyadenylation sitesManisha Yadav, Mona A AlQazzaz, Felipe E Ciamponi, et al.
Cancer Cell|September 19, 2019
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M GliomasBrian Krug, Nicolas De Jay, Ashot S Harutyunyan, et al.
The Journal of Clinical Investigation|June 15, 2026
Tumor-derived cell-free DNA detected in cerebrospinal fluid enables minimally invasive profiling of pediatric brain tumorsLiana Nobre, Yoshiko Nakano, Ian Burns, et al.
Nature Communications|August 23, 2020
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancerQin Wu, Wail Ba-Alawi, Genevieve Deblois, et al.
Cell|April 18, 2020
Roadmap for the Emerging Field of Cancer NeuroscienceMichelle Monje, Jeremy C Borniger, Nisha J D'Silva, et al.
Nature Communications|May 27, 2023
macroH2A2 antagonizes epigenetic programs of stemness in glioblastomaAna Nikolic, Francesca Maule, Anna Bobyn, et al.
Cancer Cell|December 3, 2015
MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing ChromatinMarco Gallo, Fiona J Coutinho, Robert J Vanner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade gliomaMatthew Mistry, Nataliya Zhukova, Daniele Merico, et al.
Nature Genetics|December 22, 2025
Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient gliomaNicholas R Fernandez, Yuan Chang, Nuno M Nunes, et al.
Pageof 23

Showing results (191-200 of 226) with videos related to

Sort By:
Pageof 23
Cancer Cell|May 16, 2019
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M GliomasBrian Krug, Nicolas De Jay, Ashot S Harutyunyan, et al.
Nucleic Acids Research|April 30, 2025
PRMT5 promotes full-length HTT expression by repressing multiple proximal intronic polyadenylation sitesManisha Yadav, Mona A AlQazzaz, Felipe E Ciamponi, et al.
Cancer Cell|September 19, 2019
Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M GliomasBrian Krug, Nicolas De Jay, Ashot S Harutyunyan, et al.
The Journal of Clinical Investigation|June 15, 2026
Tumor-derived cell-free DNA detected in cerebrospinal fluid enables minimally invasive profiling of pediatric brain tumorsLiana Nobre, Yoshiko Nakano, Ian Burns, et al.
Nature Communications|August 23, 2020
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancerQin Wu, Wail Ba-Alawi, Genevieve Deblois, et al.
Cell|April 18, 2020
Roadmap for the Emerging Field of Cancer NeuroscienceMichelle Monje, Jeremy C Borniger, Nisha J D'Silva, et al.
Nature Communications|May 27, 2023
macroH2A2 antagonizes epigenetic programs of stemness in glioblastomaAna Nikolic, Francesca Maule, Anna Bobyn, et al.
Cancer Cell|December 3, 2015
MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing ChromatinMarco Gallo, Fiona J Coutinho, Robert J Vanner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade gliomaMatthew Mistry, Nataliya Zhukova, Daniele Merico, et al.
Nature Genetics|December 22, 2025
Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient gliomaNicholas R Fernandez, Yuan Chang, Nuno M Nunes, et al.
Pageof 23